title: A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.
abstract: BACKGROUND
  Daclizumab (DAC) is a mAb that binds to CD25, a receptor on the surface of lymphocytes for IL-2, a chemical messenger in the immune system. This prevents activation and proliferation of lymphocytes, which are involved in the immune attack in multiple sclerosis (MS).
  
  
  METHODS
  In this review, we will focus on newly emerging DAC-high-yield process (HYP) therapy for MS. Based on published original articles and citable meeting abstracts, we will discuss its mode of action as well as data on efficacy and safety.
  
  
  CONCLUSIONS
  DAC has been observed to have multiple (biological) effects, which may contribute to beneficial effects in immune-related disease and particularly in relapsing-remitting MS. The positive results in the clinical studies represent achievement of an important milestone in the development of DAC-HYP as a potential new treatment option for MS patients. The benefit/risk ratios of this new biological agent in MS therapy are still being evaluated. Soon, DAC-HYP might qualify as MS therapy. A safety monitoring program is recommended in the clinical practice.
authors.affiliation: RKU - Universitäts- und Rehabilitationskliniken Ulm , Oberer Eselsberg 45, 89081 Ulm , Germany.
authors.forename: Emanuele
authors.initials: E
authors.lastname: D'Amico
authors.forename: Silvia
authors.initials: S
authors.lastname: Messina
authors.forename: Cinzia
authors.initials: C
authors.lastname: Caserta
authors.forename: Francesco
authors.initials: F
authors.lastname: Patti
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D000077561:Daclizumab; D016903:Drug Monitoring; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007166:Immunosuppressive Agents / Q000276:immunology / Q000494:pharmacology; D053645:Interleukin-2 Receptor alpha Subunit / Q000037:antagonists & inhibitors / Q000276:immunology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D053645:Interleukin-2 Receptor alpha Subunit; D000077561:Daclizumab
keywords: daclizumab; mAb; multiple sclerosis; safety